Shares of Sarepta Therapeutics (SRPT) slid 6% Friday morning as European regulators called for a pause in some testing of the biopharmaceutical firm's muscular dystrophy drug, Elevidys, following the death of a patient last month.

Sarepta said authorities in 澳洲幸运5开奖号码历史查询:European Union (EU) reference member countries "requested that the independent data monitoring committee (DMC) ꦅmeet to review the adverse event." It added that while that information is finalized, 🍬"recruitment and dosing in certain clinical studies of ELEVIDYS are temporarily halted."

The company reported March 18 that a patient with Duchenne muscular dystrophy who was taking Elevidys died of acute liver failure (ALF). Sarepta noted then that "acute liver injury is a kno💝wn possible side effect of Elevidys" and other similar gene therapies, although this was the first time a death had been reported of anyone taking theಌ drug.

3 Clinical Trials Halted

Three clinical studies are affected by the halt. The company explained that monitoring and data collection for participants already enrolled is continuing, and it does "not anticipate a material impact on the timeline for these studies."

Sarepta Pharmaceuticals shares plunged following the March 18 announcement and now are trading at their lowest level in more than seven years.